Détail du document
Identifiant
oai:pubmedcentral.nih.gov:1086...
Sujet
Case ReportAuteur
Uslu, S.Langue
enEditeur
The Publishing House of the Romanian Academy
Catégorie
Acta Endocrinologica (Bucharest
Année
2024
Date de référencement
25/03/2024
Mots clés
ada thyroidRésumé
The introduction of tumor necrosis factor-alpha (TNF-α) targeting drugs has given new opportunities in the treatment of various inflammatory rheumatic diseases and has been the most important development in the treatment of ankylosing spondylitis (AS).
However, the increasing use and longer follow-up periods of treatment also pose risks of developing various adverse effects, ranging from common ones, including infections, to uncommon thyroid neoplasms.
Adalimumab (ADA), a fully human monoclonal antibody targeted against TNF-α, is indicated for AS.
We describe the case of a patient with AS who developed a papillary thyroid carcinoma (PTC) while on therapy with ADA.
Cervical lymphadenopathy and a heterogeneous nodule in the right thyroid lobe were detected in the 48-year-old female patient who had been using ADA (40 mg subcutaneously every 2 weeks) for 2 years with the diagnosis of AS.
Fine-needle aspiration cytology confirmed PTC.
ADA treatment was discontinued, and a total thyroidectomy surgery was performed.
We believe that the thyroid gland should also be taken into consideration while screening for malignancy before and during TNF inhibitors (TNFi).
Uslu, S., 2024, PAPILLARY THYROID CARCINOMA FOLLOWING ADALIMUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: A CAUSAL OR COINCIDENTAL ASSOCIATION?, The Publishing House of the Romanian Academy
Configurable Safety Tuning of Language Models with Synthetic Preference Data
data preference cst dpo configurable language safety
Affective flexibility as a developmental building block of cognitive reappraisal: An fMRI study
cognitive success affective flexibility
